Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
J Mol Biol ; 435(13): 168113, 2023 07 01.
Article in English | MEDLINE | ID: covidwho-2298054

ABSTRACT

Vaccines are among the greatest tools for prevention and control of disease. They have eliminated smallpox from the planet, decreased morbidity and mortality for major infectious diseases like polio, measles, mumps, and rubella, significantly blunted the impact of the COVID-19 pandemic, and prevented viral induced cancers such as cervical cancer caused by human papillomavirus. Recent technological advances, in genomics, structural biology, and human immunology have transformed vaccine development, enabling new technologies such as mRNA vaccines to greatly accelerate development of new and improved vaccines. In this review, we briefly highlight the history of vaccine development, and provide examples of where advances in genomics and structural biology, paved the way for development of vaccines for bacterial and viral diseases.


Subject(s)
Molecular Biology , Viral Vaccines , Virus Diseases , Humans , COVID-19/prevention & control , Molecular Biology/history , Molecular Biology/trends , Pandemics , Virus Diseases/history , Virus Diseases/prevention & control , Viral Vaccines/history
3.
Sci Transl Med ; 13(579)2021 02 03.
Article in English | MEDLINE | ID: covidwho-1112312

ABSTRACT

Development of safe and effective COVID-19 vaccines is a global priority and the best hope for ending the COVID-19 pandemic. Remarkably, in less than 1 year, vaccines have been developed and shown to be efficacious and are already being deployed worldwide. Yet, many challenges remain. Immune senescence and comorbidities in aging populations and immune dysregulation in populations living in low-resource settings may impede vaccine effectiveness. Distribution of vaccines among these populations where vaccine access is historically low remains challenging. In this Review, we address these challenges and provide strategies for ensuring that vaccines are developed and deployed for those most vulnerable.


Subject(s)
COVID-19 Vaccines/immunology , COVID-19/immunology , COVID-19/virology , Disease Susceptibility , SARS-CoV-2/physiology , Animals , COVID-19 Vaccines/adverse effects , Disease Models, Animal , Humans , Phylogeny
SELECTION OF CITATIONS
SEARCH DETAIL